New drug indication could net more than $1 billion December 05, 2016 By Christine Blank FDA’s approval of a new indication for empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) could net the pharmaceutical manufacturers more than $1 billion. Breast cancer biosimilar shows equivalency to brand December 02, 2016 By Christine Blank Two new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency. FDA approves 2 injectable diabetes drugs November 28, 2016 By Christine Blank Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA. Multidrug-resistant HIV drug on the horizon November 18, 2016 By Christine Blank After a successful phase 3 study, a breakthrough therapy to treat multi-drug resistant (MDR) HIV-1 is expected to launch in the United States in 2017. Novel drug reduces monthly migraine days November 18, 2016 By Christine Blank A global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches. Gilead promises generic versions of new hepatitis drug November 11, 2016 By Christine Blank After Gilead received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. That is good news for Gilead, which has been targeted by Congressional representatives for the high cost of Sovaldi and Harvoni hepatitis C treatments. Breakthrough lymphoma drug on the horizon November 11, 2016 By Christine Blank FDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma. Insulin makers accused of price collusion November 07, 2016 By Christine Blank U.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices. Statin prescribing varies in patients with diabetes Wide variation exists in practice-level statin prescribing for patients with diabetes, according to a new study. Insurer diabetes program engages consumers, lowers costs Anthem Blue Cross recently launched a year-long diabetes prevention program to educate, treat and support its qualified California members who are at risk of developing type 2 diabetes.